Synapse
⌘+K
Synapse
PulseExploreClubsResearchersJournals
Instagram
HomeClubsExplore
December 8, 2025BloodOpen Access

Efficacy and safety of chimeric antigen receptor (CAR) T-cell therapy in richter transformation: A systematic review and meta-analysis

View Full Paper
Ask AI
Bookmark
Share

Authors

KDKarna DesaiSGSandeep GuntukuASAnubhuti Sharma

Discussion

Loading...

Member takes

Overview

Systematic review shows CAR T-cell therapy improves overall survival in Richter transformation, suggesting it may benefit patients with CLL complications.

Key Points

  • CAR T-cell therapy demonstrates significant efficacy with an overall response rate of 68% in patients with Richter transformation.
  • At one-year follow-up, the progression-free survival and overall survival rates were 43.7% and 52.5%, respectively, highlighting its long-term potential.
  • Meta-analysis utilized data from four studies, analyzing outcomes of CAR T-cell therapy in chronic lymphocytic leukemia transformed cases.
  • Encouraging findings point to the need for larger trials and standardized methods for evaluating CAR T-therapy safety.

Cite This Study

Desai et al. (2025) studied this question.

synapsesocial.com/papers/69362f444fa91c937236d626https://doi.org/10.1182/blood-2025-7658
View Full Paper
Ask AI
Bookmark
Share

Also Consider

Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context:

  1. 1Multi-centre real-world outcome of patients with Richter transformation receiving CD19-directed commercial CAR T-cell therapy in Australia.2025
  2. 2CAR-T Cell Therapy Versus Salvage Chemotherapy in Relapsed/Refractory DLBCL: A Systematic Review and Meta-Analysis Integrating Radiologic, Laboratory, and Histopathologic Correlates.2026
  3. 3Immune exhaustion limits CD19 CAR-T efficacy in Richter's transformation2025
  4. 4Safety and efficacy of anti-CD19 chimeric antigen receptor (CAR) T-cell therapy in relapsed or refractory B-cell lymphomas: A systematic review and meta-analysis2025
  5. 5Efficacy and Safety of CAR T-cell Therapy in Relapsed/Refractory B-cell Acute Lymphoblastic Leukemia: A Systematic Review and Meta-analysis2025